Bivalirudin Trifluoroacetic Acid Salt

CAS: 1124915-67-8

Ref. TR-B591630

Produktinformation

• Name: Bivalirudin Trifluoroacetic Acid Salt
• Synonyme: D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-a-aspartyl-L-phenylalanyl-L-a-glutamyl-L-a-glutamyl-L-isoleucyl-L-prolyl-L-a-glutamyl-L-a-glutamyl-L-tyrosyl-L-leucine Trifluoroacetic Acid Salt, Angiomax, Angiox, BG 8967, Hirulog, Hirulog1, Kangio
• CAS: 1124915-67-8

Beschreibung

Applications Bivalirudin Trifluoroacetic Acid Salt is an anticoagulant drug that is a direct thrombin inhibitor. It is used for treatment of acute coronary syndromes, and is a safer alternative to heparin due to lower rates of bleeding as an adverse effect of anticoagulant in patients.
References Stone, G., et al.: N. Engl. J. Med, 355, 2203 (2006); Stone, G., et al.: N Engl J Med, 358, 2218 (2008);

• Marke: TRC

Chemische Eigenschaften

• Molekulargewicht: 2180.2911402
• Formel: C₉₈H₁₃₈N₂₄O₃₃·(CHF₃O₂)
• Farbe/Form: Neat
• InChl: InChI=1S/C98H137N24O33.C2HF3O2/c1-5-52(4)82(95(152)121-38-14-22-69(121)92(149)113-59(30-34-79(134)135)85(142)110-58(29-33-78(132)133)86(143)115-63(42-55-24-26-56(123)27-25-55)89(146)117-66(96(153)154)40-51(2)3)118-87(144)60(31-35-80(136)137)111-84(141)57(28-32-77(130)131)112-88(145)62(41-53-16-8-6-9-17-53)116-90(147)65(45-81(138)139)109-76(129)50-106-83(140)64(44-71(99)124)108-75(128)49-105-73(126)47-103-72(125)46-104-74(127)48-107-91(148)68-21-13-37-120(68)94(151)61(20-12-36-102-98(100)101)114-93(150)70-23-15-39-122(70)119-67(97(155)156)43-54-18-10-7-11-19-54;3-2(4,5)1(6)7/h6-11,16-19,24-27,51-52,57-70,82,119,123,156H,5,12-15,20-23,28-49H2,1-4H3,(H2,99,124)(H,103,125)(H,104,127)(H,105,126)(H,106,140)(H,107,148)(H,108,128)(H,109,129)(H,110,142)(H,111,141)(H,112,145)(H,113,149)(H,114,150)(H,115,143)(H,116,147)(H,117,146)(H,118,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,153,154)(H4,100,101,102);(H,6,7)/t52-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-;/m0./s1/i156+1
• InChI Key: InChIKey=ULVSLKSXUBAKNX-OCPYWBNVSA-N